关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 青岛蔚蓝龙初生物科技有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 2,700.00 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 900.00 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | 115,020.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 66.19% | | 特别风险提示（如有请勾选） | 对外担保总额（含本次）超过上市公司最近一 | | | ...

Group 1 - The company has indicated that it does not have products or research investments specifically targeting plastic degradation [2] - The company emphasizes the application of microbial technology in the environmental sector and has established the Blue Biological Environmental Microbial Laboratory [2] - The focus is on combining microbial technology with environmental technology to effectively remove various pollutants through the metabolic processes of specific microorganisms [2] Group 2 - The company aims to achieve green and low-carbon governance of various water environments and biological deodorization in multiple scenarios [2] - Currently, the revenue from this business segment is relatively small [2]

每经AI快讯，有投资者在投资者互动平台提问：公司的宠物驱虫药氟雷拉纳滴剂等产品显示了研发实 力。但宠物市场不仅是产品之争，更是品牌和渠道之争。请问在宠物板块，公司如何规划自有品牌 （2C）与代工（2B）的业务比重？ 是满足于做'隐形冠军'，还是有打造直面消费者的知名宠物健康品 牌的长期战略？ 在渠道建设上，是主要依托传统的线下兽医院渠道，还是已积极布局线上直营（如天 猫、京东旗舰店）？近期是否有增加与大型宠物医院连锁机构的合作计划？ 蔚蓝生物（603739.SH）10月14日在投资者互动平台表示，公司正积极布局宠物动保产品，已拟定长期 的产品规划方案，涉及化药、生物制品和宠物保健品等领域。公司宠物动保产品目前以自有品牌的生产 销售为主，不涉及代工业务。同时，公司将逐步健全研发与市场运营团队，开展推广以线下兽医院为主 的渠道建设。公司将严格按照《上海证券交易所股票上市规则》等相关规定进行公告，及时履行信息披 露义务，有关信息请以公司在上海证券交易所网站披露的相关公告为准。 （记者 胡玲） ...

蔚蓝生物（603739.SH）10月14日在投资者互动平台表示，公司不存在生物可降解材料（如PHA）的业 务布局或生物基单体的研发项目。公司更多具体产品或项目信息请查阅公司在上海证券交易所网站披露 的定期报告。公司将严格按照《上海证券交易所股票上市规则》等相关规定进行公告，及时履行信息披 露义务，有关信息请以公司在上海证券交易所网站披露的相关公告为准。 （记者 胡玲） 每经AI快讯，有投资者在投资者互动平台提问：我们关注到，公司在2024年年报中提及"合成生物学技 术平台"是核心发展方向之一，而工信部等六部门也明确要求推动生物基材料研发与产业化。请问公 司： 在该平台下，关于生物可降解材料（如PHA）或生物基单体的研发目前是否已进入中试或产业化 准备阶段？ 是否有计划利用该技术平台，响应政策号召，向生物基化工材料领域进行拓展？ ...

证券日报网讯 9月29日晚间，蔚蓝生物发布公告称，截至本公告日，公司无逾期担保事项。 （文章来源：证券日报） ...

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-042 青岛蔚蓝生物股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 担保对象一 | 被担保人名称 | | 青岛康地恩动物药业有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 3,000.00 | 万元 | | | | 实际为其提供的担保余额 | 6,654.81 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担保对象二 | 被担保人名称 | | | 青岛蔚蓝生物集团有限公司 | | | 本次担保金额 | 5,000.00 | 万元 | | | | 实际为其提供的担保余额 | 19,597.15 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-043 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛康 地恩动物药业有限公司、青岛动保国家工程技术研究中心有限公司与其他单位联 合申报的"青霉素 V 钾可溶性粉"为五类新兽药，并于近日核发了《新兽药注册 证书》（农业农村部公告第 953 号）。 一、新兽药的基本信息 研制单位：青岛蔚蓝生物股份有限公司、江苏南农高科动物药业有限公司、 山东亚康药业股份有限公司、烟台金海药业有限公司、青岛康地恩动物药业有限 公司、河北科星药业有限公司、山东德州神牛药业有限公司、山东中农普宁药业 有限公司、山东天宇生物科技有限公司、河南省晨源生物科技有限公司、青岛润 达生物科技有限公司、中国农业科学院兰州畜牧与兽药研究所、青岛动保国家工 程技术研究中心有限公司。 新兽药注册证书号：（2025）新兽 ...

Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the joint application of Qingdao Weilan Biological Co., Ltd. and other units for "Potassium Penicillin V Soluble Powder" as a new veterinary drug of category five, indicating a significant step in addressing the urgent market demand for effective treatments for necrotic enteritis in chickens [1] Group 1: Product Development - The product is specifically designed for the treatment of necrotic enteritis in chickens, a condition that currently lacks effective treatment options [1] - A total investment of 2.8067 million yuan has been made in the research and development of this product [1] - The product is notable for being usable during the laying period, having a short withdrawal period, high safety, and convenient dosage form [1] Group 2: Market Implications - There is a pressing market demand for medications that can be used during the egg-laying period, highlighting the product's potential to fill a significant gap in the market [1] - The issuance of the new veterinary drug certificate reflects the company's innovative capabilities and is expected to contribute to new revenue growth [1] - The product still requires approval of the product registration number before it can be marketed [1]

Core Viewpoint - The biocatalyst industry is experiencing significant growth due to its high efficiency, selectivity, and environmental friendliness, with applications in biotechnology, pharmaceuticals, and food processing [1][4][12]. Biocatalyst Industry Definition and Characteristics - Biocatalysts refer to free or immobilized cells and enzymes that catalyze biological reactions, including various types such as free enzymes, immobilized enzymes, microbial cells, and plant and animal cells [2][4]. Current Development Status of the Biocatalyst Industry - Biocatalysts are highly efficient compared to traditional chemical catalysts, with reaction rates potentially increasing by millions of times when enzymes are involved [4][12]. - In 2024, China's biocatalyst production is projected to reach 195,000 tons, an increase of 12,000 tons from 2023, while demand is expected to rise to 178,000 tons, up by 6,000 tons [5][7]. Biocatalyst Industry Supply Chain - The upstream of the biocatalyst industry includes the supply of fermentation strains, enzyme raw materials, and production equipment, while the midstream focuses on the manufacturing of biocatalysts, and the downstream encompasses applications in pharmaceuticals, food processing, bioenergy, and molecular biology research [7][8]. Competitive Landscape of the Biocatalyst Industry - The biocatalyst industry in China is characterized by intense competition, with multinational companies like Novozymes and DuPont dominating the high-end market, while local firms such as Guangdong Yidoli and Qingdao Blue Biological are expanding their market share through technological innovation [9][10]. Development Trends in the Biocatalyst Industry - Biocatalysts are seen as sustainable alternatives to traditional chemical processes, driven by increasing environmental concerns and regulatory pressures, leading to a surge in demand for biocatalysts in various sectors [12][13]. - The market for biocatalysts is expected to grow as consumer preferences shift towards sustainable and bio-based products, although challenges such as catalyst stability and long development cycles remain [12].